Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
2,603 results
  • Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. [Review]
    Prostate Cancer Prostatic Dis 2019Iravani A, Violet J, … Hofman MS
  • Theranostic principles utilize a molecular biomarker specific for a tumor target, initially for imaging to assess target expression and, if deemed suitable, for targeted therapy. This presents an exciting opportunity for a highly personalized treatment strategy in the era of precision medicine. Prostate-specific membrane antigen (PSMA) theranostics has attracted increasing attention as a promisin…
  • A novel small molecule inhibits tumor growth and synergizes effects of enzalutamide on prostate cancer. [Journal Article]
    J Pharmacol Exp Ther 2019Cheng J, Moore S, … Cashman JR
  • Prostate cancer (PCa) is the second leading cause of cancer-related death for men in the United States. About 35% of PCa recurs and is often transformed to castrate-resistant PCa (CRPCa), the most deadly and aggressive form of PCa. However, the standard-of-care treatment for CRPCa (e.g., enzalutamide with abiraterone) usually has limited efficacy. Herein, we report a novel molecule (i.e., PAWI-2)…
  • Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? [Review]
    Ther Adv Med Oncol 2019; 11:1758835919876828Alipour R, Azad A, Hofman MS
  • Radiolabelled small molecules for imaging prostate cancer have rapidly emerged over the last few years with gallium-68-labelled prostate-specific-membrane-antigen-11 (68Ga-PSMA11), the most widely used. However, the current evidence-based guidelines for management of prostate cancer were established using computed tomography (CT), magnetic resonance imaging (MRI) and bone scan, despite their limi…
  • Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells. [Journal Article]
    Biochem Biophys Res Commun 2019; 519(3):579-584Smith KW, Thompson PD, … Cobice DF
  • Prostate cancer is initially treated via androgen deprivation therapy (ADT), a highly successful treatment in the initial pursuit of tumor regression, but commonly restricted by the eventual emergence of a more lethal 'castrate resistant' form of the disease. Intracrine pathways that utilize dehydroepiandrosterone (DHEA) or other circulatory precursor steroids, are thought to generate relevant le…
New Search Next